98%
921
2 minutes
20
Background: There is limited and inconsistent information on the prevalence of cognitive impairment in neuromyelitis optica spectrum disorders (NMOSD).
Objective: To assess cognitive performance and changes over time in NMOSD.
Methods: This study included data from 217 aquaporin-4-IgG-seropositive (80%) and double-seronegative NMOSD patients. Cognitive functions measured by Symbol Digit Modalities Test (SDMT), Paced Auditory Serial-Addition Task (PASAT), and/or Multiple Sclerosis Inventory Cognition (MuSIC) were standardized against normative data ( = 157). Intraindividual cognitive performance at 1- and 2-year follow-up was analyzed. Cognitive test scores were correlated with demographic and clinical variables and assessed with a multiple linear regression model.
Results: NMOSD patients were impaired in SDMT ( = 0.007), MuSIC semantic fluency ( < 0.001), and MuSIC congruent speed ( < 0.001). No significant cognitive deterioration was found at follow-up. SDMT scores were related to motor and visual disability ( < 0.05). No differences were found between aquaporin-4-IgG-seropositive and double-seronegative NMOSD.
Conclusions: A subset of NMOSD patients shows impairment in visual processing speed and in semantic fluency regardless of serostatus, without noticeable changes during a 2-year observation period. Neuropsychological measurements should be adapted to physical and visual disabilities.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10278388 | PMC |
http://dx.doi.org/10.1177/13524585231151212 | DOI Listing |
Neurol Neuroimmunol Neuroinflamm
November 2025
Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden.
Background And Objectives: Myelitis is a relatively common clinical entity for neurologists, with diverse underlying causes. The aim of this study was to describe the incidence of myelitis, its causes, clinical presentation, and factors predicting functional outcomes and relapses.
Methods: Using the Swedish National Patient Registry, we identified all adult patients in Stockholm County between 2008 and 2018 using International Classification of Diseases, 10th Edition (ICD-10) codes likely to include myelitis.
Mult Scler
September 2025
Department of Neurology, Neurological Clinical Research Institute, Massachusetts General Hospital, Boston, MA, USA.
Background: Financial toxicity (FT) and the social determinants of health (SDOH) remain underexplored in neuromyelitis optica spectrum disorder (NMOSD).
Objective: To characterize FT in NMOSD and examine sociodemographic and clinical features.
Methods: We conducted a convenience-sampled, cross-sectional, anonymous survey (08/2024-03/2025) of 124 U.
Neurol Neurochir Pol
September 2025
Institute of Medical Sciences, Collegium Medicum, University of Zielona Góra, Zielona Góra, Poland.
Clin Neurol Neurosurg
October 2025
Department of Neurology, University Hospitals Leuven, Leuven, Belgium.
We present the case of a 54-year-old patient treated with cemiplimab, an immune checkpoint inhibitor (ICI), for multiple basal cell carcinomas in the context of Gorlin Goltz syndrome. Gorlin Goltz syndrome is an autosomal dominant multisystem disorder characterized, among other features, by multiple early-onset basal cell carcinomas (BCCs). After receiving Cemiplimab, she developed aquaporin-4 antibody (AQP4-Ab) positive neuromyelitis optica spectrum disorder (NMOSD).
View Article and Find Full Text PDFMult Scler Relat Disord
September 2025
Neurologist-Neuroimmunologist. Associate Professor of Neurology, Neuroscience Department, Division of Neurology, Pontificia Universidad Javeriana, Hospital Universitario San Ignacio, Bogotá, Colombia. Electronic address:
Background: Headache is a common but underrecognized symptom in optic neuritis (ON), with potential implications for diagnosis and management.
Objective: To assess the clinical and radiological factors associated with headache in patients with acute ON.
Methods: We conducted a retrospective case-control study in a tertiary hospital in Bogotá, Colombia (2022-2024).